Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
A phase 2 trial of Ivonescimab, Olaparib in ovarian cancer, run by Akeso, now recruiting.
Overview
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer is a phase 2 interventional study registered as NCT06686030 by Akeso, with 150 participants planned, started 2025-02-17 and due to reach its primary completion in 2027-10. Interventions recorded: AK112 low dose, Chemotherapy, Olaparib, AK112 high dose. Conditions listed: Platinum-sensitive Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Ivonescimab, Akeso, Ovarian cancer.
- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Akeso.
- TrialAK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Shares Ivonescimab, Akeso.
- TrialA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Shares Ivonescimab, Akeso.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares Olaparib, Ovarian cancer.
- TrialD9319C00001- 1L OC Mono Global RCT
Shares Olaparib, Ovarian cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso.